AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23575004 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 184
Study 22257756 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure Precise™ vessel sealing system
Number of subjects: 40
Study 22257756 — intervention group
Group type: COMPARATOR
Intervention: Conventional suture ligatures
Number of subjects: 40
Study 19175784 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosin
Number of subjects: 43
Study 19175784 — intervention group
Group type: COMPARATOR
Intervention: Topical Steroids
Number of subjects: 43
Study 17595435 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral amino acids at 1.5 g/kg/d for >24 hours
Number of subjects: 122
Study 17595435 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral amino acids at 3 g/kg/d for short (5 hours), extended (24 hours), or prolonged (3-5 days) duration
Number of subjects: 122
Study 17595435 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with large patent ductus arteriosus (PDA)
Number of subjects: 122
Study 17595435 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age, weight loss, and patent ductus arteriosus
Number of subjects: 122
Study 16306548 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg/day
Number of subjects: 20
Study 16306548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12666487 — intervention group
Group type: EXPERIMENTAL
Intervention: PDSII loop suture
Number of subjects: 0
Study 12666487 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous suture with Vicryl
Number of subjects: 0
Study 12666487 — intervention group
Group type: COMPARATOR
Intervention: Classical suture by individual silone stitches
Number of subjects: 0
Study 10480960 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure reducing foam mattresses (PRFMs)
Number of subjects: 18
Study 8694986 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-Bright toothbrush
Number of subjects: 28
Study 8694986 — intervention group
Group type: COMPARATOR
Intervention: Oral-B 35 toothbrush (Control)
Number of subjects: 28
Study 2038927 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline (0.05, 0.1, 0.2, 0.3 and 0.5 ml)
Number of subjects: 17
Study 2038927 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle insertions using different needle sizes (20 G, 23 G and 30 G)
Number of subjects: 17
Study 2038927 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.75% (0.1 ml, 30 G needle)
Number of subjects: 17
Study 2038927 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% (0.1 ml, 30 G needle)
Number of subjects: 17
Study 2038927 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% (0.1 ml, 30 G needle)
Number of subjects: 17
Study 2038927 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.25% (0.1 ml, 30 G needle)
Number of subjects: 17
Study 152937 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 liters of fluid intravenously just prior to myelography
Number of subjects: 100
Study 152937 — intervention group
Group type: COMPARATOR
Intervention: No intravenous fluids (control group)
Number of subjects: 100
Study 31319554 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal supplementation of 6000 IU/day vitamin D3
Number of subjects: 95
Study 31319554 — intervention group
Group type: COMPARATOR
Intervention: Maternal supplementation of 600 IU/day plus infant supplementation of 400 IU/day vitamin D3
Number of subjects: 95
Study 25453586 — intervention group
Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa 30U/kg
Number of subjects: 11
Study 25453586 — intervention group
Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa 60U/kg
Number of subjects: 11
Study 23481298 — intervention group
Group type: EXPERIMENTAL
Intervention: Checkpoints intervention
Number of subjects: 148
Study 23481298 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 148
Study 21949036 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanofi‐Aventis branded enoxaparin (SAe) 40 mg subcutaneously once daily for 7 to 10 days
Number of subjects: 200
Study 21949036 — intervention group
Group type: COMPARATOR
Intervention: eurofarma‐enoxaparin (Ee) 40 mg subcutaneously once daily for 7 to 10 days
Number of subjects: 200
Study 19885423 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard edgewise appliances
Number of subjects: 39
Study 19885423 — intervention group
Group type: COMPARATOR
Intervention: Straight-wire appliance
Number of subjects: 39
Study 16717175 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microg of hemagglutinin
Number of subjects: 202
Study 16717175 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg of hemagglutinin
Number of subjects: 202
Study 16717175 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 microg of hemagglutinin
Number of subjects: 202
Study 16717175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 16179274 — intervention group
Group type: EXPERIMENTAL
Intervention: VDR TaqI Tt or tt genotype
Number of subjects: 140
Study 16179274 — intervention group
Group type: COMPARATOR
Intervention: Regular aerobic exercise
Number of subjects: 140
Study 12538426 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum from patients with acute coronary syndromes (group 3)
Number of subjects: 113
Study 12538426 — intervention group
Group type: EXPERIMENTAL
Intervention: Trolox
Number of subjects: 113
Study 12538426 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 serum
Number of subjects: 113
Study 12538426 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (after 1 year)
Number of subjects: 113
Study 10418767 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition (n = 116) - viewed a video depicting risk factors for sexual assault
Number of subjects: 224
Study 10418767 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n = 108) - viewed a video without risk factors for sexual assault
Number of subjects: 224
Study 10418767 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessment (n = 66)
Number of subjects: 224
Study 7473485 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methotrexate (MTX) after fasting
Number of subjects: 14
Study 7473485 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methotrexate (MTX) after feeding
Number of subjects: 14
Study 7473485 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methotrexate (MTX)
Number of subjects: 14
Study 2188774 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 20
Study 2188774 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride
Number of subjects: 20
Study 7023520 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimeprazine tartrate 2 mg kg‐1 plus atropine 0.03 mg kg‐1
Number of subjects: 192
Study 7023520 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimeprazine tartrate 4 mg kg‐1 plus atropine 0.03 mg kg‐1
Number of subjects: 192
Study 7023520 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimeprazine tartrate 4 mg kg‐1
Number of subjects: 192
Study 7023520 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimeprazine tartrate 2 mg kg‐1
Number of subjects: 192
Study 7023520 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimeprazine tartrate 2 mg kg‐1 and 4 mg kg‐1
Number of subjects: 192
Study 31894037 — intervention group
Group type: EXPERIMENTAL
Intervention: Kuntai capsules (4 capsules per time, 3 times a day)
Number of subjects: 120
Study 31894037 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium enteric‐coated tablets (25mg, 3 times a day)
Number of subjects: 120
Study 28847895 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Artery Calcium (CAC) testing
Number of subjects: 8801
Study 28847895 — intervention group
Group type: COMPARATOR
Intervention: Functional Testing (FT)
Number of subjects: 8801
Study 28847895 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomographic angiography
Number of subjects: 8801
Study 26738329 — intervention group
Group type: EXPERIMENTAL
Intervention: Shugan Yiyang Capsules combined with sertraline hydrochloride 50 mg qd
Number of subjects: 192
Study 26738329 — intervention group
Group type: COMPARATOR
Intervention: sertraline hydrochloride 50 mg qd
Number of subjects: 192
Study 23361162 — intervention group
Group type: COMPARATOR
Intervention: 0.4 g/kg alcohol (low dose)
Number of subjects: 40
Study 23361162 — intervention group
Group type: COMPARATOR
Intervention: 0.8 g/kg alcohol (high dose)
Number of subjects: 40
Study 23361162 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (no alcohol)
Number of subjects: 40
Study 21401214 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine 20 mg/dimenhydrinate 40 mg (fixed combination)
Number of subjects: 182
Study 21401214 — intervention group
Group type: COMPARATOR
Intervention: Cinnarizine 20 mg (monotherapy)
Number of subjects: 182
Study 21401214 — intervention group
Group type: COMPARATOR
Intervention: Dimenhydrinate 40 mg (monotherapy)
Number of subjects: 182
Study 19059567 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10mg/day) with patient counselling on diet
Number of subjects: 1496
Study 19059567 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10mg/day) with patient counselling on physical exercise
Number of subjects: 1496
Study 19059567 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10mg/day) with patient counselling on both diet and physical exercise
Number of subjects: 1496
Study 19059567 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 1496
Study 16584288 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (250 mg sustained-release capsule) after overnight fasting
Number of subjects: 24
Study 16584288 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (250 mg sustained-release capsule) after standard breakfast
Number of subjects: 24
Study 16584288 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (250 mg sustained-release capsule) after high-fat breakfast
Number of subjects: 24
Study 14563545 — intervention group
Group type: EXPERIMENTAL
Intervention: Subutex 2 mg
Number of subjects: 90
Study 14563545 — intervention group
Group type: EXPERIMENTAL
Intervention: Subutex 8 mg
Number of subjects: 90
Study 14563545 — intervention group
Group type: EXPERIMENTAL
Intervention: Subutex 12 mg
Number of subjects: 90
Study 14563545 — intervention group
Group type: EXPERIMENTAL
Intervention: Subutex 16 mg
Number of subjects: 90
Study 14563545 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboxone 8 mg/naloxone 2 mg
Number of subjects: 90
Study 14563545 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone 50-150 mg
Number of subjects: 90
Study 11090789 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg/day for 4 weeks
Number of subjects: 18
Study 11090789 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks followed by Losartan 50 mg/day for 4 weeks
Number of subjects: 18
Study 8616130 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia trachomatis IgG antibodies (titre > or = 1/32) in patients
Number of subjects: 349
Study 8616130 — intervention group
Group type: COMPARATOR
Intervention: Chlamydia trachomatis IgG antibodies (titre > or = 1/32) in controls
Number of subjects: 349
Study 8616130 — intervention group
Group type: EXPERIMENTAL
Intervention: C. pneumoniae antibodies
Number of subjects: 349
Study 1329697 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 2766 (2 mg administered subcutaneously on days 1 and 10 for non-Hodgkin's lymphoma; days 1 and 8 for Hodgkin's disease)
Number of subjects: 28
Study 1329697 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 mg administered subcutaneously on days 1 and 10 for non-Hodgkin's lymphoma; days 1 and 8 for Hodgkin's disease)
Number of subjects: 28
Study 6426405 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day for 2 years (in premenopausal status, after oophorectomy)
Number of subjects: 422
Study 6426405 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with mitomycin C 20 mg/m2, iv, followed by cyclophosphamide 60 mg/m2, po
Number of subjects: 422
Study 6426405 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tamoxifen and chemotherapy
Number of subjects: 422
Study 6426405 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone or combination of chemotherapy and tamoxifen
Number of subjects: 422
Study 29799105 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual self-care training
Number of subjects: 60
Study 29799105 — intervention group
Group type: COMPARATOR
Intervention: Control group (no spiritual self-care training)
Number of subjects: 60
Study 29674307 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth interventions (apps)
Number of subjects: 33
Study 27759092 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild electrical stimulation (MES) with heat shock (HS) treatment, 2 treatments per week for 12 weeks
Number of subjects: 60
Study 27759092 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild electrical stimulation (MES) with heat shock (HS) treatment, 4 treatments per week for 12 weeks
Number of subjects: 60
Study 27759092 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild electrical stimulation (MES) with heat shock (HS) treatment, 7 treatments per week for 12 weeks
Number of subjects: 60
Study 27759092 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild electrical stimulation (MES) with heat shock (HS) treatment (combined groups)
Number of subjects: 60
Study 27759092 — intervention group
Group type: COMPARATOR
Intervention: Mild electrical stimulation (MES) with heat shock (HS) treatment, 7 treatments per week
Number of subjects: 60
Study 24509965 — intervention group
Group type: EXPERIMENTAL
Intervention: ingenol mebutate 0.015% gel
Number of subjects: 329
Study 24509965 — intervention group
Group type: COMPARATOR
Intervention: vehicle
Number of subjects: 329
Study 22744392 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for fungal keratitis
Number of subjects: 0
Study 20233439 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 30
Study 20233439 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 30
Study 20233439 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 30
Study 18394692 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (EI)
Number of subjects: 236
Study 18394692 — intervention group
Group type: COMPARATOR
Intervention: Minimal Intervention (MI)
Number of subjects: 236
Study 16140684 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS prevalence in Heilongjiang province (14.02%)
Number of subjects: 5403
Study 16140684 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS prevalence in children 12 years and younger (11.86%)
Number of subjects: 5403
Study 16140684 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS prevalence in minority students (21.15%)
Number of subjects: 5403
Study 16140684 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to coldness
Number of subjects: 5403
Study 12940924 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine or mercaptopurine (MP) treatment
Number of subjects: 56
Study 12940924 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients who tolerated azathioprine or MP)
Number of subjects: 56
Study 12219878 — intervention group
Group type: EXPERIMENTAL
Intervention: DRSP/E2 + ENA
Number of subjects: 24
Study 12219878 — intervention group
Group type: COMPARATOR
Intervention: Placebo + ENA
Number of subjects: 24
Study 10076125 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg estradiol combined with 50 microg gestodene
Number of subjects: 278
Study 10076125 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg estradiol combined with 25 microg gestodene
Number of subjects: 278
Study 10076125 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg estradiol combined with 25 microg gestodene (sequentially)
Number of subjects: 278
Study 10076125 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg estradiol combined with 25 microg gestodene (continuously)
Number of subjects: 278
Study 10076125 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg estradiol combined with 25 microg gestodene
Number of subjects: 278
Study 10076125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 7488566 — intervention group
Group type: EXPERIMENTAL
Intervention: Elaborate procedural test training
Number of subjects: 34
Study 7488566 — intervention group
Group type: COMPARATOR
Intervention: Monetary reinforcement added to test training
Number of subjects: 34
Study 2274626 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg/day to a maximum of 200 mg/day)
Number of subjects: 87
Study 2274626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 6167028 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 50
Study 6167028 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with bleomycin
Number of subjects: 50
Study 31895773 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible health education programs with WeChat Social Messaging platform
Number of subjects: 168
Study 31895773 — intervention group
Group type: COMPARATOR
Intervention: Regular prenatal examination and health education programs
Number of subjects: 168
Study 31791386 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg
Number of subjects: 498
Study 31791386 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib 30 mg
Number of subjects: 498
Study 31791386 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 498
Study 27814453 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily fluticasone (F)
Number of subjects: 493
Study 27814453 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily fluticasone plus salmeterol (F + S)
Number of subjects: 493
Study 27814453 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily oral montelukast (M)
Number of subjects: 493
Study 26464041 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 ml ropivacaine 0.375%
Number of subjects: 56
Study 26464041 — intervention group
Group type: COMPARATOR
Intervention: 60 ml isotonic saline
Number of subjects: 56
Study 25306116 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea and vitamin C supplements
Number of subjects: 50
Study 25306116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 22564671 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain signal (colored slide indicating possible pain stimulus)
Number of subjects: 36
Study 22564671 — intervention group
Group type: COMPARATOR
Intervention: Safety signal (colored slide indicating no pain stimulus)
Number of subjects: 36
Study 22564671 — intervention group
Group type: EXPERIMENTAL
Intervention: Observers with high catastrophizing about others' pain
Number of subjects: 36
Study 22564671 — intervention group
Group type: EXPERIMENTAL
Intervention: Observers with heightened psychopathic traits
Number of subjects: 36
Study 19304578 — intervention group
Group type: EXPERIMENTAL
Intervention: Larval therapy (bagged larvae, loose larvae)
Number of subjects: 267
Study 19304578 — intervention group
Group type: COMPARATOR
Intervention: Hydrogel
Number of subjects: 267
Study 17436362 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture (RA) at Siguan points (bilateral LI4 and LR3)
Number of subjects: 20
Study 17436362 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 20
Study 15389896 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐beta1a
Number of subjects: 172
Study 15389896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 11606914 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg anti-CD11a monoclonal antibody
Number of subjects: 145
Study 11606914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 9552136 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional pancreatic enzyme replacement therapy (3 capsules of 8,000 FIP units Creon)
Number of subjects: 11
Study 9552136 — intervention group
Group type: EXPERIMENTAL
Intervention: High-lipase pancreatic enzyme replacement therapy (1 capsule of 25,000 FIP units)
Number of subjects: 11
Study 9552136 — intervention group
Group type: COMPARATOR
Intervention: No enzyme intake (control)
Number of subjects: 11
Study 7844208 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/day LHRHa (Decapeptyl) for 14 days followed by 0.5 mg/day LHRHa during folliculogenesis (group A)
Number of subjects: 42
Study 7844208 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg/day LHRHa (Decapeptyl) for 14 days followed by 0.1 mg/day LHRHa during folliculogenesis (group B)
Number of subjects: 42
Study 2897940 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 278
Study 2897940 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 278
Study 29456086 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Dose Propofol (LDP)
Number of subjects: 66
Study 29456086 — intervention group
Group type: COMPARATOR
Intervention: Standard Therapy (ST)
Number of subjects: 66
Study 27425010 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine C-peptide/creatinine ratio
Number of subjects: 0
Study 27425010 — intervention group
Group type: COMPARATOR
Intervention: Stimulated serum C-peptide level
Number of subjects: 0
Study 27425010 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-dose-adjusted HbA1c level
Number of subjects: 0
Study 24275953 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretest probability estimates for acute coronary syndrome and pulmonary embolism with suggested clinical actions
Number of subjects: 550
Study 24275953 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 550
Study 24275953 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (pretest probability estimates)
Number of subjects: 550
Study 22712208 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief bright light (BL) exposure on workday mornings
Number of subjects: 0
Study 22712208 — intervention group
Group type: COMPARATOR
Intervention: Non-BL periods
Number of subjects: 0
Study 21122661 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 14
Study 21122661 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy patients)
Number of subjects: 14
Study 19069579 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT)
Number of subjects: 608